Comparative Analysis of Bunyavirus Neuropathogenesis
布尼亚病毒神经发病机制的比较分析
基本信息
- 批准号:10675190
- 负责人:
- 金额:$ 114.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-24 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAfricaAgeAnimalsAntiviral ResponseArbovirusesBiological ModelsBrainCategory A pathogenCell DeathCellsCentral Nervous System DiseasesCentral Nervous System InfectionsChildhoodCulicidaeDengueDependenceDiseaseDisease OutbreaksEpidemicFeverFlavivirusFutureGenomeGoalsHealthHumanImmunologistIn VitroIndividualInfectionInnate Immune ResponseInsect VectorsKnowledgeLa Crosse virusMediatingMedicalMolecularMorbidity - disease rateMusNational Institute of Allergy and Infectious DiseaseNeuraxisNeurobiologyNeurologicNeuronsNeuropathogenesisNonstructural ProteinNorth AmericaOropouche virusOrthobunyavirusPathogenesisPathogenicityPathway interactionsProteinsPublishingResearchRift Valley FeverRift Valley fever virusRodentRoleRouteSliceSouth AmericaSurvivorsSystemTropismUnited StatesVariantViralViral EncephalitisVirulenceVirulentVirusVirus Diseasesage relatedantagonistcell typecellular targetingchikungunyaclimate changecomparativeglobal healthhuman pathogeninduced pluripotent stem cellinhibitorinnate immune pathwaysinterdisciplinary approachlong-term sequelaemortalitymouse modelnervous system disorderneurovirulencenovelorganizational structurepathogenprotein functionprototyperesponsestemtranscriptomicsvector-bornevirology
项目摘要
PROJECT SUMMARY/ABSTRACT
Bunyaviruses are a large, diverse group of vector-borne viruses with the capacity to cause neurological disease
with morbidity and mortality. A major limitation in our basic scientific understanding of bunyavirus
neuropathogenesis stems from the fact that key target cells in the brain are not fully defined, therefore the effect
of infection on target cells is unknown, and viral determinants that contribute to neurological disease have not
been delineated. A broader, understanding of how bunyaviruses interact with the central nervous system (CNS),
including molecular mechanisms of host-viral interactions, is fundamental for future goal of mitigating effects of
disease and long-term sequelae in survivors. Here, we propose a comparative analysis of the basic
neuropathogenesis of 3 important emerging bunyaviruses: Rift Valley fever (RVFV), Oropouche (OROV), and
La Crosse (LACV). Infection by each of these viruses have the potential to cause significant neurological disease
in humans. However, substantial gaps remain in our understanding of bunyavirus neuropathogenesis, including
molecular mechanisms that contribute to disease. A limitation is the lack of rigor of prior research is that published
studies on these viruses as they are difficult to directly compare due to use of different in vitro cell systems and
disparate mouse models, including variations in age and infection route. We will address this gap by directly
comparing CNS cell tropism, innate responses, and cell death pathways induced by RVFV, OROV, and LACV
using novel in vitro and ex vivo model systems. Given the potential for diverse bunyaviruses to cause
neurological sequelae in a subset of human cases, and the fact that all 3 are lethal in neurological mouse models,
we hypothesize that diverse bunyaviruses have common target cells in the CNS and that neuronal infection is
mediated by Lrp1, a newly identified host entry factor for RVFV. A key feature of bunyaviral virology is the
expression of the viral non-structural protein produced from the small genome segment (NSs). NSs is the main
antagonist of host cell antiviral responses. Each virus expresses a different NSs protein, and thus we further
hypothesize that the degree of neurovirulence of each virus is directly related to NSs protein function, with RVFV
NSs being the most potent inhibitor of innate responses. Our highly collaborative and synergistic team is led by
Dr. Amy Hartman (PI), an expert in the pathogenesis of RVFV, Dr. Anita McElroy (Co-I), a molecular virologist
and immunologist with expertise in emerging viral diseases, Dr. Gaya Amarasinghe (Co-I), a biochemist with
expertise in host-pathogen interactions. Two additional Co-I’s are Dr. Leonard D’Aiuto and Dr. Zachary Wills,
who are experts in viral infection of human neurons and rodent neurobiology, respectively. This R01 proposal
represents a multidisciplinary approach to advance our understanding of bunyavirus interactions with the brain.
项目概要/摘要
布尼亚病毒是一大类多样化的媒介传播病毒,能够引起神经系统疾病
与发病率和死亡率。我们对布尼亚病毒的基本科学理解的一个主要限制
神经发病机制源于大脑中关键靶细胞尚未完全确定的事实,因此影响
of infection on target cells is unknown, and viral determinants that contribute to neurological disease have not
被划定。对布尼亚病毒如何与中枢神经系统 (CNS) 相互作用有更广泛的了解,
包括宿主与病毒相互作用的分子机制,对于未来减轻病毒影响的目标至关重要
幸存者的疾病和长期后遗症。在此,我们对基本情况进行比较分析
3 种重要的新兴布尼亚病毒的神经发病机制:裂谷热 (RVFV)、奥罗普切病毒 (OROV) 和
拉克罗斯 (LACV)。这些病毒的感染都有可能导致严重的神经系统疾病
在人类中。然而,我们对布尼亚病毒神经发病机制的理解仍然存在很大差距,包括
导致疾病的分子机制。一个局限性是先前研究缺乏严谨性,即已发表的研究
对这些病毒的研究,因为由于使用不同的体外细胞系统而很难直接比较它们
不同的小鼠模型,包括年龄和感染途径的差异。我们将通过直接解决这一差距
比较 RVFV、OROV 和 LACV 诱导的 CNS 细胞趋向性、先天反应和细胞死亡途径
使用新颖的体外和离体模型系统。鉴于多种布尼亚病毒可能导致
在部分人类病例中会出现神经系统后遗症,而且这三种情况在神经系统小鼠模型中都是致命的,
我们假设不同的布尼亚病毒在中枢神经系统中有共同的靶细胞,并且神经元感染是
由 Lrp1 介导,Lrp1 是一种新发现的 RVFV 宿主进入因子。布尼亚病毒学的一个关键特征是
由小基因组片段(NS)产生的病毒非结构蛋白的表达。 NS是主要的
宿主细胞抗病毒反应的拮抗剂。每种病毒表达不同的 NSs 蛋白,因此我们进一步
假设每种病毒的神经毒力程度与 NSs 蛋白功能直接相关,其中 RVFV
NS 是先天反应最有效的抑制剂。我们高度协作和协同的团队由以下人员领导
Amy Hartman 博士(PI),RVFV 发病机制专家,Anita McElroy 博士(Co-I),分子病毒学家
Gaya Amarasinghe 博士 (Co-I) 是一位生物化学家,在新兴病毒性疾病方面拥有丰富的专业知识。
宿主与病原体相互作用方面的专业知识。另外两位 Co-I 是 Leonard D’Aiuto 博士和 Zachary Wills 博士,
他们分别是人类神经元病毒感染和啮齿动物神经生物学方面的专家。这个R01提案
代表了一种多学科方法,以增进我们对布尼亚病毒与大脑相互作用的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy L Hartman其他文献
Amy L Hartman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy L Hartman', 18)}}的其他基金
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses
原型新兴布尼亚病毒感染神经元的机制
- 批准号:
10728597 - 财政年份:2023
- 资助金额:
$ 114.92万 - 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
- 批准号:
10447151 - 财政年份:2021
- 资助金额:
$ 114.92万 - 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
- 批准号:
10286235 - 财政年份:2021
- 资助金额:
$ 114.92万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10356824 - 财政年份:2020
- 资助金额:
$ 114.92万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10673312 - 财政年份:2020
- 资助金额:
$ 114.92万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10113532 - 财政年份:2020
- 资助金额:
$ 114.92万 - 项目类别:
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever
神经保护性抗炎药物作为神经裂谷热的新型联合疗法
- 批准号:
9915980 - 财政年份:2017
- 资助金额:
$ 114.92万 - 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
- 批准号:
9002103 - 财政年份:2015
- 资助金额:
$ 114.92万 - 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
- 批准号:
8891769 - 财政年份:2015
- 资助金额:
$ 114.92万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 114.92万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 114.92万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 114.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 114.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 114.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




